DPP-4 Inhibitors for Type 2 Diabetes Treatment

DPP-4 inhibitors are a class of oral diabetes medications that lower blood sugar by blocking the enzyme dipeptidyl peptidase-4, which normally breaks down hormones that help regulate insulin. Approved members of the class include sitagliptin, saxagliptin, vildagliptin, alogliptin, and linagliptin. They occupy a middle ground in type 2 diabetes treatment: effective enough to meaningfully lower HbA1c, gentle enough that they rarely cause low blood sugar or weight gain, yet lacking the dramatic cardiovascular and kidney benefits that have made newer drug classes the center of attention. Understanding where DPP-4 inhibitors fit, and where they fall short, matters for anyone taking one or weighing their options.

How DPP-4 Inhibitors Work

After you eat, your gut releases hormones called incretins, the most important being GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones signal the pancreas to release insulin and dial back glucagon, a hormone that raises blood sugar. The problem is that a ubiquitous enzyme called DPP-4 chews up GLP-1 within minutes of its release. DPP-4 inhibitors block that enzyme, preventing the breakdown of GLP-1 and keeping its levels elevated for longer. The result is more insulin when blood sugar is high and less glucagon pushing sugar into the bloodstream.¹

This mechanism is sometimes called “incretin enhancement,” and it differs fundamentally from the approach used by GLP-1 receptor agonists like semaglutide or liraglutide. Those drugs mimic GLP-1 directly by flooding the body with a synthetic version of the hormone at pharmacological doses. DPP-4 inhibitors instead preserve whatever GLP-1 your body already makes, which means they work at physiological concentrations.² That distinction explains a lot of the practical differences between the two classes: GLP-1 agonists produce stronger blood sugar reductions and significant weight loss, while DPP-4 inhibitors are milder in both effect and side effects.

How Much They Lower Blood Sugar

Across a large meta-analysis of 98 trials involving more than 24,000 patients, DPP-4 inhibitors reduced HbA1c by an average of about 0.77 percentage points from a baseline around 8%.³ That is a clinically meaningful drop, though not as large as what you would see with GLP-1 agonists or SGLT2 inhibitors at full doses. Roughly 40% of participants in controlled trials reached the commonly used HbA1c target of below 7%, and the single best predictor of how much benefit someone gets is their starting HbA1c: the higher it is, the larger the drop.⁴

When added to metformin, DPP-4 inhibitors perform comparably to sulfonylureas and thiazolidinediones in terms of HbA1c reduction, without the weight gain that accompanies those older drugs.⁵ The practical ceiling, however, is real. If your HbA1c is well above 9%, a DPP-4 inhibitor alone or even paired with metformin is unlikely to get you to target. These drugs work best for people whose blood sugar is moderately elevated and who need a second or third agent that will not rock the boat.

The Safety Advantage Over Sulfonylureas

For decades, sulfonylureas like glipizide and glyburide were the standard add-on to metformin. They are cheap and effective, but they force the pancreas to secrete insulin regardless of blood sugar level, which creates two well-known problems: hypoglycemia and weight gain. DPP-4 inhibitors sidestep both. Because they work through the incretin system, they stimulate insulin release only when blood sugar is already elevated. Once glucose normalizes, the insulin signal fades.

A systematic review and meta-analysis comparing the two classes found that when combined with metformin, DPP-4 inhibitors had roughly one-tenth the risk of severe low blood sugar events compared to sulfonylureas. Overall adverse events, cardiovascular events, and hypoglycemia of any severity were all lower with DPP-4 inhibitors. Additionally, patients on DPP-4 inhibitors did not gain the weight that sulfonylurea users typically did.⁶ A separate real-world cohort study found that sulfonylurea users had higher crude rates of severe hypoglycemia, cardiovascular events, and death compared to DPP-4 inhibitor users.⁷

This safety profile makes DPP-4 inhibitors especially appealing for older adults, people who live alone (where unrecognized low blood sugar is dangerous), and anyone who has had episodes of hypoglycemia on other medications. Weight neutrality is also a practical benefit; adding a drug that does not pile on pounds matters when obesity is already driving the diabetes.

Cardiovascular Outcomes

After some older diabetes drugs were found to increase heart risk, regulators began requiring large cardiovascular outcome trials for all new glucose-lowering medications. Three major trials tested DPP-4 inhibitors (alogliptin, saxagliptin, and sitagliptin) in patients with type 2 diabetes and high cardiovascular risk. All three showed that their respective drug was no worse than placebo for major cardiovascular events, but none showed any protective benefit either.⁸ In the language of clinical trials, they met noninferiority but not superiority.

The saxagliptin trial (SAVOR-TIMI 53) introduced a wrinkle that still influences prescribing decisions. In that trial, more patients randomized to saxagliptin were hospitalized for heart failure compared to placebo, with rates of 3.5% versus 2.8%.⁹ This signal triggered widespread concern about the class as a whole. However, subsequent real-world data complicated the picture. A large retrospective cohort study found that saxagliptin users were actually less likely to be hospitalized for heart failure than users of sitagliptin, pioglitazone, sulfonylureas, or insulin.¹⁰ The discrepancy between the trial finding and the observational data has never been fully resolved. Most clinicians now avoid saxagliptin in patients with existing heart failure as a precaution while feeling more comfortable with sitagliptin or linagliptin in that scenario.

When compared head-to-head against sulfonylureas rather than placebo, DPP-4 inhibitors showed a lower risk of major adverse cardiovascular events. One retrospective study found an adjusted hazard ratio of 0.84, meaning about a 16% lower risk.¹¹ Against metformin, there was no significant difference. The overall picture is that DPP-4 inhibitors are cardiovascularly safe, a meaningful improvement over sulfonylureas, but they do not deliver the active heart protection seen with SGLT2 inhibitors or GLP-1 agonists.

Adverse Effects Worth Knowing About

DPP-4 inhibitors are generally well tolerated, but they are not free of concerns. Post-marketing surveillance using the FDA’s adverse event reporting system has flagged signals for pancreatitis, cardiac failure (particularly with saxagliptin), a blistering skin condition called bullous pemphigoid, acute kidney injury, and hypoglycemia when combined with other glucose-lowering agents.¹²

Bullous pemphigoid deserves specific mention because it is an unusual side effect that most patients and some prescribers are unaware of. This autoimmune blistering disease causes large, itchy blisters on the skin and primarily affects older adults. A study of patients with diabetes in Korea found that those prescribed a DPP-4 inhibitor had roughly 1.6 times the odds of developing bullous pemphigoid compared to controls. Among the individual drugs, vildagliptin carried the highest association, followed by sitagliptin and linagliptin.¹³ The absolute risk remains low, but the association is consistent enough that any new unexplained blistering in someone taking a DPP-4 inhibitor should prompt consideration of the drug as a cause.

The Joint Pain Question

The FDA issued a safety communication in 2015 warning that DPP-4 inhibitors might cause severe joint pain. The evidence here is genuinely mixed. One study of diabetic patients found that DPP-4 inhibitor users had nearly four times the risk of developing arthritis or joint pain compared to non-users, with the risk rising for each year of use.¹⁴ A large retrospective study of older veterans also found a statistically significant, though more modest, increase in joint pain among DPP-4 inhibitor users.¹⁵

However, a propensity-matched cohort study comparing DPP-4 inhibitor starters to people starting other diabetes drugs found no meaningful difference in overall musculoskeletal conditions.¹⁶ The picture seems to be that some individuals develop joint symptoms on these drugs, and the FDA warning is not baseless, but the risk is not large enough to show up consistently across well-controlled comparisons. If you develop new or worsening joint pain after starting a DPP-4 inhibitor, it is worth flagging to your prescriber; the pain typically resolves after stopping the medication.

Kidney Disease and Dose Adjustments

Kidney function matters with most DPP-4 inhibitors because the drugs and their metabolites are primarily cleared through the kidneys. When kidney function declines, plasma levels of the drug can rise substantially, in some cases by up to sevenfold in people with severe impairment.¹⁷ For sitagliptin, saxagliptin, and alogliptin, dose reductions are required at various thresholds of kidney impairment. The one exception is linagliptin, which is eliminated primarily through the liver and bile rather than the kidneys, making it the go-to DPP-4 inhibitor for patients with chronic kidney disease who do not need dose adjustment.

This renal consideration is worth understanding because type 2 diabetes and kidney disease travel together. By the time many patients need a second or third diabetes drug, their kidneys may already be under strain, sometimes limiting their options. The fact that at least one DPP-4 inhibitor works at full dose regardless of kidney function is a genuine practical advantage.

How They Compare to SGLT2 Inhibitors

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) have largely overshadowed DPP-4 inhibitors in treatment guidelines because they do more than lower blood sugar. They reduce the risk of heart failure hospitalization, slow kidney disease progression, and promote modest weight loss. Both classes carry a low risk of hypoglycemia, but that is where the similarities end.

In terms of raw glucose-lowering power, combining an SGLT2 inhibitor with a DPP-4 inhibitor produces a larger HbA1c reduction than either drug alone. A recent meta-analysis found the combination lowered HbA1c by about 0.57 percentage points more than a DPP-4 inhibitor alone and 0.46 percentage points more than an SGLT2 inhibitor alone, with no added hypoglycemia risk.¹⁸ The weight loss seen with the combination came entirely from the SGLT2 inhibitor component; adding the DPP-4 inhibitor did not reduce weight further but also did not interfere with it.¹⁹

Animal research also suggests the combination may offer kidney protection beyond what either drug provides separately. In a mouse model of diabetic kidney disease, the combination of dapagliflozin and saxagliptin reduced markers of kidney damage more than dapagliflozin alone, partly by tamping down inflammatory pathways.²⁰ Whether those preclinical findings translate into better kidney outcomes in humans remains to be confirmed.

Oral Convenience and Patient Preference

One underappreciated advantage of DPP-4 inhibitors is sheer simplicity. They are taken as a once-daily pill, with or without food, and do not require blood sugar monitoring beyond what your doctor already recommends. Compare that to GLP-1 receptor agonists, most of which require weekly or daily injection, and it is easy to see why some patients prefer a DPP-4 inhibitor even when a GLP-1 agonist might be more potent.

A crossover study pitting vildagliptin (a DPP-4 inhibitor in pill form) against liraglutide (an injectable GLP-1 agonist) found overall preference split almost evenly. But among patients 65 and older, about two-thirds preferred the oral DPP-4 inhibitor.²¹ Needle aversion, dexterity issues, and the nausea that frequently accompanies GLP-1 agonist initiation all push older patients toward pills. Oral semaglutide has partially closed this gap, but it comes with strict dosing requirements (take on an empty stomach, wait 30 minutes before eating) that make it less convenient than a DPP-4 inhibitor for some people.

The Immune System Connection

DPP-4 is not just a metabolic enzyme. It is also known as CD26, a protein found on the surface of most T cells that plays an active role in immune function. CD26/DPP-4 helps activate T cells, triggers their proliferation, and mediates interactions between T cells and antigen-presenting cells.²² Beyond T cells, CD26 has been found to play roles in other immune cells as well.²³

This dual identity raises a natural question: does blocking DPP-4 with a diabetes drug affect your immune system? The honest answer is that the clinical consequences, if any, appear subtle. The bullous pemphigoid association may be one manifestation, since that disease is autoimmune in nature. But large-scale clinical trials have not revealed any clear pattern of increased infections or immune suppression in people taking DPP-4 inhibitors. The enzyme has more than 30 known substrates across various tissues, and the drug’s effects on the immune side of DPP-4 activity are still being worked out.²⁴

Possible Neuroprotective Effects

One of the more intriguing areas of research involves the brain. Type 2 diabetes is a well-established risk factor for cognitive decline and dementia, and there is growing interest in whether incretin-based therapies might offer some degree of neuroprotection. A meta-analysis found that DPP-4 inhibitors significantly reduced the incidence of cognitive impairment in people with type 2 diabetes, with improvements correlating with better control of fasting glucose, postmeal glucose, and HbA1c.²⁵

Animal studies have gone further, suggesting that the mechanism might involve more than just glucose control. In a mouse model of Alzheimer’s disease, a DPP-4 inhibitor improved learning and memory while reducing beta-amyloid accumulation and abnormal tau phosphorylation, both hallmarks of Alzheimer’s pathology. These effects were linked to enhanced GLP-1 signaling in the hippocampus and cortex.²⁶ This line of research is still early, and the animal findings have not been confirmed in rigorous human trials designed specifically to test cognitive outcomes. But the signal is there, and it adds an interesting layer to the story of these drugs beyond blood sugar.

Effects on the Liver

DPP-4 levels in the blood tend to be elevated in people with various liver conditions, including non-alcoholic fatty liver disease, hepatitis C, and hepatocellular carcinoma. Researchers have explored whether inhibiting DPP-4 might have beneficial effects on liver health, especially since fatty liver disease and type 2 diabetes so frequently coexist. Early evidence suggests DPP-4 inhibitors may improve liver enzyme levels and insulin resistance in the liver, though the data are not mature enough to support using them specifically for liver disease treatment.²⁷ For now, this represents another area where the biology is suggestive and the clinical evidence is catching up.

Where DPP-4 Inhibitors Fit in Current Treatment

The landscape of type 2 diabetes treatment has shifted dramatically since sitagliptin became the first approved DPP-4 inhibitor.²⁸ Guidelines now prioritize SGLT2 inhibitors and GLP-1 receptor agonists for patients with established cardiovascular or kidney disease, because those classes have proven benefits beyond glucose control. DPP-4 inhibitors have been pushed down the priority list in those high-risk groups.

But the drugs have not become irrelevant. They remain a reasonable choice for patients who cannot tolerate metformin and need something gentle, for older adults who prefer oral medication with minimal side effects, for people with moderate kidney disease (especially linagliptin), and for patients whose primary need is modest additional glucose lowering without the gastrointestinal side effects of GLP-1 agonists. Cost also matters: generic sitagliptin became available in some markets as patents expire, potentially narrowing the price gap with older drugs. In many countries, DPP-4 inhibitors remain cheaper than branded GLP-1 agonists and SGLT2 inhibitors, which keeps them in heavy use globally even as Western guidelines favor the newer classes.